TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06343792: Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

Sponsor: ReAlta Life Sciences, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 66 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,460,800

Rescue Site Savings

+$962,800

Unlock Full NCT06343792 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06343792 Rescue Dossier →